177 related articles for article (PubMed ID: 35182475)
21. Effectiveness of Antipsychotic Use for Reducing Risk of Work Disability: Results From a Within-Subject Analysis of a Swedish National Cohort of 21,551 Patients With First-Episode Nonaffective Psychosis.
Solmi M; Taipale H; Holm M; Tanskanen A; Mittendorfer-Rutz E; Correll CU; Tiihonen J
Am J Psychiatry; 2022 Dec; 179(12):938-946. PubMed ID: 36200276
[TBL] [Abstract][Full Text] [Related]
22. Real-world effectiveness of antidepressants, antipsychotics and their combinations in the maintenance treatment of psychotic depression. Evidence from within-subject analyses of two nationwide cohorts.
Taipale H; Lieslehto J; Lähteenvuo M; Hamina A; Tanskanen A; Mittendorfer-Rutz E; Paljärvi T; Solmi M; Cipriani A; Correll CU; Tiihonen J
World Psychiatry; 2024 Jun; 23(2):276-284. PubMed ID: 38727044
[TBL] [Abstract][Full Text] [Related]
23. Representation and Outcomes of Individuals With Schizophrenia Seen in Everyday Practice Who Are Ineligible for Randomized Clinical Trials.
Taipale H; Schneider-Thoma J; Pinzón-Espinosa J; Radua J; Efthimiou O; Vinkers CH; Mittendorfer-Rutz E; Cardoner N; Pintor L; Tanskanen A; Tomlinson A; Fusar-Poli P; Cipriani A; Vieta E; Leucht S; Tiihonen J; Luykx JJ
JAMA Psychiatry; 2022 Mar; 79(3):210-218. PubMed ID: 35080618
[TBL] [Abstract][Full Text] [Related]
24. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).
Tiihonen J; Lönnqvist J; Wahlbeck K; Klaukka T; Niskanen L; Tanskanen A; Haukka J
Lancet; 2009 Aug; 374(9690):620-7. PubMed ID: 19595447
[TBL] [Abstract][Full Text] [Related]
25. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia.
Gaebel W; Riesbeck M; Wölwer W; Klimke A; Eickhoff M; von Wilmsdorff M; Jockers-Scherübl MC; Kühn KU; Lemke M; Bechdolf A; Bender S; Degner D; Schlösser R; Schmidt LG; Schmitt A; Jäger M; Buchkremer G; Falkai P; Klingberg S; Köpcke W; Maier W; Häfner H; Ohmann C; Salize HJ; Schneider F; Möller HJ;
J Clin Psychiatry; 2007 Nov; 68(11):1763-74. PubMed ID: 18052570
[TBL] [Abstract][Full Text] [Related]
26. Risk Factors, Incidence, and Outcomes of Neuroleptic Malignant Syndrome on Long-Acting Injectable vs Oral Antipsychotics in a Nationwide Schizophrenia Cohort.
Guinart D; Taipale H; Rubio JM; Tanskanen A; Correll CU; Tiihonen J; Kane JM
Schizophr Bull; 2021 Oct; 47(6):1621-1630. PubMed ID: 34013325
[TBL] [Abstract][Full Text] [Related]
27. Discontinuation of antipsychotics in individuals with first-episode schizophrenia and its association to functional outcomes, hospitalization and death: a register-based nationwide follow-up study.
Stürup AE; Nordentoft M; Jimenez-Solem E; Osler M; Davy JW; Christensen TN; Speyer H; Albert N; Hjorthøj C
Psychol Med; 2023 Aug; 53(11):5033-5041. PubMed ID: 35818718
[TBL] [Abstract][Full Text] [Related]
28. Long-term Continuity of Antipsychotic Treatment for Schizophrenia: A Nationwide Study.
Rubio JM; Taipale H; Tanskanen A; Correll CU; Kane JM; Tiihonen J
Schizophr Bull; 2021 Oct; 47(6):1611-1620. PubMed ID: 34129663
[TBL] [Abstract][Full Text] [Related]
29. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis.
Leucht S; Tardy M; Komossa K; Heres S; Kissling W; Salanti G; Davis JM
Lancet; 2012 Jun; 379(9831):2063-71. PubMed ID: 22560607
[TBL] [Abstract][Full Text] [Related]
30. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder.
Robinson D; Woerner MG; Alvir JM; Bilder R; Goldman R; Geisler S; Koreen A; Sheitman B; Chakos M; Mayerhoff D; Lieberman JA
Arch Gen Psychiatry; 1999 Mar; 56(3):241-7. PubMed ID: 10078501
[TBL] [Abstract][Full Text] [Related]
31. [Comparison of medical and economic benefits of antipsychotics in the treatment of schizophrenia in France].
Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
Encephale; 2017 Aug; 43(4):311-320. PubMed ID: 27623123
[TBL] [Abstract][Full Text] [Related]
32. Comparative Effectiveness of Antipsychotics for Risk of Attempted or Completed Suicide Among Persons With Schizophrenia.
Taipale H; Lähteenvuo M; Tanskanen A; Mittendorfer-Rutz E; Tiihonen J
Schizophr Bull; 2021 Jan; 47(1):23-30. PubMed ID: 33428766
[TBL] [Abstract][Full Text] [Related]
33. Change in antipsychotic usage pattern and risk of relapse in older patients with schizophrenia.
Talaslahti T; Alanen HM; Hakko H; Isohanni M; Häkkinen U; Leinonen E
Int J Geriatr Psychiatry; 2013 Dec; 28(12):1305-11. PubMed ID: 23558986
[TBL] [Abstract][Full Text] [Related]
34. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness and costs of flupentixol compared to other first- and second-generation antipsychotics in the treatment of schizophrenia.
Stargardt T; Mavrogiorgou P; Gericke CA; Juckel G
Psychopharmacology (Berl); 2011 Aug; 216(4):579-87. PubMed ID: 21432026
[TBL] [Abstract][Full Text] [Related]
36. Continuity of antipsychotic medication use among migrant and Finnish-born populations with a psychotic disorder: a register-based study.
Lehti V; Taipale H; Gissler M; Tanskanen A; Elonheimo M; Tiihonen J; Suvisaari J
Psychol Med; 2023 Feb; 53(3):833-843. PubMed ID: 34074352
[TBL] [Abstract][Full Text] [Related]
37. Psychosocial and psychological interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis.
Bighelli I; Rodolico A; García-Mieres H; Pitschel-Walz G; Hansen WP; Schneider-Thoma J; Siafis S; Wu H; Wang D; Salanti G; Furukawa TA; Barbui C; Leucht S
Lancet Psychiatry; 2021 Nov; 8(11):969-980. PubMed ID: 34653393
[TBL] [Abstract][Full Text] [Related]
38. Real-world Effectiveness of Pharmacologic Treatments for the Prevention of Rehospitalization in a Finnish Nationwide Cohort of Patients With Bipolar Disorder.
Lähteenvuo M; Tanskanen A; Taipale H; Hoti F; Vattulainen P; Vieta E; Tiihonen J
JAMA Psychiatry; 2018 Apr; 75(4):347-355. PubMed ID: 29490359
[TBL] [Abstract][Full Text] [Related]
39. Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence.
Si T; Li N; Lu H; Cai S; Zhuo J; Correll CU; Zhang L; Feng Y
J Psychopharmacol; 2018 Jun; 32(6):691-701. PubMed ID: 29764266
[TBL] [Abstract][Full Text] [Related]
40. 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20).
Taipale H; Tanskanen A; Mehtälä J; Vattulainen P; Correll CU; Tiihonen J
World Psychiatry; 2020 Feb; 19(1):61-68. PubMed ID: 31922669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
